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Abstract
Vascular endothelial dysfunction is a key component initiating oxidative stress in 
ischemia/reperfusion (I/R). Endothelial dysfunction is characterized by an increase in 
hydrogen peroxide (H2O2) and a decrease in the bioavailability of nitric oxide (NO). 
Previous studies using protein kinase C (PKC) inhibitor Gö 6983 or PKC Beta (β) II
inhibitor improved cardiac function in myocardial I/R, decreased leukocyte-endothelial 
interactions and leukocyte superoxide (SO) release and increased endothelial-derived NO
release in vitro. This study examined the effects of Gö 6983 or PKC β II inhibitor on real-
time H2O2 and NO release in femoral vein I/R in vivo. NO or H2O2 microsensors (100 μm 
diameter) were inserted into both femoral veins in the anesthetized rat. One femoral vein 
was subjected to I/R, which was induced by clamping the femoral artery and vein for 20 
min (ischemia) followed by removing the clamp for 45 min (reperfusion). The other, non-
ischemic femoral vein served as a sham control in the same animal. H2O2 release
significantly increased in the I/R limb compared to the sham limb in the control group by
2-2.8 M during reperfusion (n=7, P<0.05). NO release showed a trend to decrease in the
I/R limb compared to the sham limb in the saline control group (n=6). Gö 6983 (7.4 
µg/kg) given at the beginning of reperfusion significantly decreased H2O2 levels to initial 
baseline levels (n=7, P<0.01) and increased NO release 100-150 nM (n=7, P<0.01) 
compared to saline control. PKC β II peptide inhibitor (0.55 mg/kg) given at the
beginning of reperfusion significantly decreased H2O2 levels to initial baseline levels
(n=7, P<0.01) and increased NO release 50-75 nM (n=6, P<0.05) compared to saline
control. Collectively, the data supports our hypothesis that inhibiting PKC with either a
broad spectrum inhibitor such as Gö 6983, or a selective inhibitor such as PKC β II, 
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attenuates oxidative stress in femoral I/R. This may be due to inhibition of
leukocyte/endothelial nicotinamide-adenine-dinucleotide phosphate (NADPH) oxidase
and increasing endothelial-derived NO release.
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Introduction
Ischemia is the process by which there is an absolute or relative shortage of blood 
supply and oxygen to an organ, resulting in damage or dysfunction to a tissue. Restoring
blood flow after an ischemic attack is essential in order to revitalize organ function in 
animal models as well as human patients. However, reperfusion injury occurs via an 
increase in oxidative stress 2 to 5 min after the onset of reperfusion, which subsequently
decreases the bioavailability of NO, resulting in endothelial dysfunction (Lefer et al. 
1996).  Endothelial dysfunction is associated with the pathophysiological process based 
in clinical cases concerning myocardial infractions, stroke, organ transplants, diabetes, 
and atherosclerosis (Matsuda et al. 2007; Schafer et al. 2008; Chen et al. 2010).
Determining the mechanisms related to endothelial dysfunction via I/R is important in 
developing new tools to limit reperfusion injury in clinical settings. 
The endothelium is a single layer of cells that lines the luminal surface of blood 
vessels. It is composed of simple squamous epithelium and has various functions such as: 
vascular tone, cell adherence, coagulation, inflammation, and permeability (Kharbanda et 
al. 2001). Vascular endothelium is thought to have arisen from the splanchnopleuric 
mesoderm and consists of approximately 1 x 10
13 
cells that comprises about a 1 kg organ 
(Sumpio et al. 2002). Dysfunctional endothelium contributes to the pathogenesis and 
complications of major chronic diseases such as cardiovascular disease that constitute the 
leading causes of death and disability worldwide (Mensah 2007).  According to the
American Heart Association, in 2010 an estimated 81,000,000 American adults have one
or more types of cardiovascular disease.  Vascular endothelial dysfunction is considered a
major initial event in these pathologies (Matsuda et al. 2007; Schafer et al. 2008). 
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Regarding femoral I/R, clinical settings such as gunshot wounds to legs, to compartment 
syndrome cause vascular endothelial dysfunction. 
Endothelial dysfunction via I/R injury is characterized by a decrease in 
endothelial release of NO and an increase in oxidative stress (i.e. increase in H2O2 
release) within 5 min after reperfusion. Other characteristics include up-regulation of 
endothelial surface adhesion molecules, increased leukocyte-endothelium interaction 
within 20 min, and transmigration of polymorphonuclear leukocytes (PMNs) into the 
reperfused tissue that starts 30 min post reperfusion (Lucchesi et al. 1986; Tsao et al. 
1990; Lefer et al. 1996; Teng et al. 2008; Chen et al. 2010). This cascade is amplified 3 to 
4 hrs which results in organ dysfunction.
Activated PMNs release SO, inflammatory cytokines, and proteolytic enzymes 
(Lucchesi et al. 1989). These events cause tissue necrosis and organ dysfunction 
following post ischemic reperfusion (Lucchesi and Mullane 1986; Lucchesi, Werns et al. 
1989). They contribute to reperfusion injury by initiating lipid peroxidation through H2O2 
formation, and they alter membrane permeability to ions such as Ca
2+ 
(Lucchesi et al. 
1986; Rubanyi et al. 1986). SO reduces the bioavailability of NO by combining with it to 
produce the peroxynitrite anion, thereby inhibiting the vasodilating effects of NO and 
resulting in endothelial dysfunction (Rubanyi et al. 1989; Tsao et al. 1992).
NO is an important signaling molecule, principally responsible for vasodilation of 
blood vessels and attenuation of the inflammation associated with reperfusion injury
(Lefer and Lefer 1996). Under normal physiological conditions, endothelial derived NO
is produced by the membrane bound enzyme endothelial nitric oxide synthase (eNOS) 
which oxidizes the amino acid L-arginine to form the intermediate N
G
-hydroxy-L­
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arginine (Govers et al. 2001). NADPH and tetrahydrobiopterin (BH4) are required 
cofactors of eNOS (Vanhoutte 2003; Channon 2004). The oxygenase domain of eNOS
normally contains the BH4 prosthetic group. NO release is facilitated via a single electron 
donation by the BH4 activated heme bound molecular oxygen (O2) (Verhaar et al. 2004).
In addition to NO, L-citrulline is the other product derived from L-arginine via eNOS. 
The synthesis and release of NO occurs in response to stimuli acting on the 
endothelial cell surface (Kharbanda et al. 2001). Acetylcholine and arachidonic acid are
chemical stimuli while physiological stimuli include shear stress (Vanhoutte 2003). 
These stimuli cause an increase in intracellular calcium which will activate eNOS to 
synthesize NO. NO, a volatile and lipophilic gas readily diffuses across the cell
membrane to adjacent smooth muscle cells and into the vascular lumen (Watson et al. 
2008). NO causes an increase in guanylate cyclase activity, resulting in greater
concentrations of cyclic 3'5' guanosine monophosphate (cGMP). Cyclic GMP is a second 
messenger that leads to dephosphorylation of myosin light chain kinase (MLCK) within 
smooth muscles, thereby leading to relaxation and vasodilation (Kharbanda and 
Deanfield 2001).
There are two additional NOS isoforms that exist in addition to eNOS, each
having a different function. Inducible NOS (iNOS) is found primarily in the immune 
system being used by macrophages, neutrophils, and other inflammatory cells. Neuronal 
NOS (nNOS) is found in the nervous tissue and functions in the transmission of NO from 
one neuron to another (Forstermann et al. 2006; Keklikoglu 2008). nNOS and eNOS are
constitutively expressed and regulated by calcium and calmodulin. They produce small
amounts of NO (i.e., nM range), which has precise actions on adjacent cells. Inducible
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NOS produces high levels of NO (i.e., M range) in response to inflammatory cytokines 
and is independent of calcium and calmodulin regulation (Mungrue et al. 2002).
Under situations of oxidative stress such as reperfusion injury eNOS uncoupling
occurs. This process by which oxidation of BH4 to dihydrobiopterin (BH2) facilitates a
switch of NO production to SO (Chen et al. 2010). Oxidation of BH4 to BH2 increases the 
BH2 to BH4 ratio allowing BH2 to displace BH4 for binding at the eNOS heme oxygenase
domain, preventing the normal flow of electrons and proper enzyme function (Vasquez-
Vivar et al. 2002) (Figure 1). Under these conditions, L-arginine is not coupled at the
heme domain of eNOS and O2 receives the electron to produce SO (Vasquez-Vivar et al. 
2002). The initial oxidation of BH4 to BH2 may be due to incomplete oxidative 
phosphorylation in mitochondria (Crabtree et al. 2008). The reduced bioavailability of 
NO leads to a decrease in vasodilation, muscle relaxation, and anti-inflammatory
processes in coronary vessels (Teng et al. 2008). A previous study using non-ischemic rat 
aortic segments showed an increase in NO release with addition of BH4. By contrast,  a 
decrease in NO was recorded when BH2 was added (Kim E.J. et al. 2007; Chen et al. 
2010).
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Figure 1. The role of BH4 in regulating eNOS activity in vascular disease. eNOS
coupling occurs during a normal setting allowing the reaction to produce NO and L­
citrulline from L-arginine /NADPH/O2. In the setting of I/R, BH2 is able to bind to 
the oxygenase domain of eNOS resulting in the production of superoxide. Note: L­
citrulline is not produced in the setting of I/R. Adapted from (Schmidt et al. 2007)
SO, a reactive oxygen species (ROS) and the product of eNOS uncoupling, is 
rapidly converted to H2O2 by superoxide dismutase (SOD) and both biomolecules cause 
cell injury through lipid peroxidation. H2O2 is the more stable oxidant that can persist for
several min before it is converted to H2O by catalase. Under normal physiological 
conditions, a delicate balance exists between ROS and antioxidant mechanisms which 
remove them (Girn et al. 2007). Oxidative stress occurs in response to disruptions in 
internal homeostasis and disrupts the balance in favor of ROS production which 
overcomes the body‟s defense mechanisms (i.e., superoxide dismutase).
The SO radical is produced by NADPH oxidase, uncoupled eNOS, xanthine
oxidase, cytochrome P-450, and dysfunctional mitochondria (Khazaei et al. 2008). 
During oxidative stress, such as early reperfusion following ischemia, the excess SO 
produced combines with NO at an extremely rapid rate to form peroxynitrite, thereby
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reducing NO bioavailability and contributing to endothelial dysfunction (Girn et al. 
2007).
NADPH oxidase, another enzyme contributing to oxidative stress is present in 
both PMNs and endothelial cells. NADPH oxidase consists of two membrane-bound 
subunits (p22phox and gp91phox) and four cytosolic subunits (p40phox, p47phox, 
p67phox, and rac1) (Qin et al. 2007). Phosphorylation of the cytosolic p47phox subunit, 
principally by PKC, leads to conformational changes allowing interactions with p22phox, 
which is essential to generate SO release. The movement of p47phox brings with it the
other cytoplasmic subunits, p67phox and p40phox, to form the active NADPH oxidase
complex (Figure 2) (Qin, Simeone et al. 2007). This family of enzyme complexes with
each of the 7 isoforms, being primarily distinguished by the membrane spanning catalytic
„Nox‟ or „Doux‟ subunit that it utilizes to transfer electrons from NADPH to O2 to 
produce  SO (Selemidis et al. 2008).
Another  part of the oxidative damage associated with dysfunctional endothelium
is upregulation of cellular adhesion molecules (CAMs) that facilitates the rolling, 
adherence, and transmigration of PMNs into the reperfused tissue (Lucchesi et al. 1986;
Ouedraogo et al. 2007; Schafer et al. 2008). Each of the three stages of leukocyte
recruitment involves different families of adhesion molecules expressed on the vascular
endothelium and on the leukocytes. These include selectins, integrins, and members of
the immunoglobulin superfamily (Panes et al. 1999).
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Figure 2. NADPH oxidase assembly via phosphorylation of p47phox to produce SO. 
Adapted from (Morena et al. 2002)
P-selectin is a member of the selectin family of CAMs (Sundd et al. 2011). 
During I/R, vascular dysfunction occurs within 5 min and the cellular adhesion molecule 
P-selectin is upregulated on the endothelial surface within 10 min (Tsao et al. 1990; Tsao 
et al. 1990). It is known to be regulated by decreased NO and PKC phosphorylation.  P­
selectin has been identified as a primary CAM responsible for leukocyte rolling along the 
endothelium of post-capillary venules. The carbohydrate side chains of the glycolipids on 
the leukocyte cell surface allow the selectin to reversibly bind. PMNs form new adhesive
interactions at the front of the molecule while breaking them at the back which allows 
them to “roll” along the endothelial monolayer (Sundd et al. 2011).
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Intercellular adhesion molecule-1 (ICAM-1) is a member of the immunoglobulin 
superfamily. During reperfusion injury, inflammatory cytokines such as TNF-alpha and 
activated PKC upregulate ICAM-1 expression within hours and it remains elevated for 24 
hours (Frey et al. 2002; Sumagin et al. 2006; Sumagin et al. 2008; Teng et al. 2008). 
ICAM-1 is a mediator of leukocyte adherence to the endothelial wall as a result of its 
binding to integrins expressed on the leukocyte surface (Panes et al. 1999; Sumagin et al. 
2008).
Platelet/endothelial cell adhesion molecule (PECAM-1), is another member of 
the immunoglobulin superfamily and has been associated with leukocyte transmigration 
through the endothelial monolayer (Panes et al. 1999).  PECAM-1 is not upregulated in 
response to endothelial dysfunction. Instead, the molecule is redistributed to the borders 
of adjoining endothelial cells where it participates in leukocyte transmigration. This 
leukocyte-endothelial cell signaling facilitates the movement of leukocytes through the 
endothelial cell and perivascular basement membrane (Romer et al. 1995; Sumagin et al. 
2008). Once across the endothelium the leukocytes can release SO, myeloperoxidase, 
elastase, matrix metalloproteinases, and cathepsins to cause cell and tissue damage (Tsao 
et al. 1990; Hirata et al. 1995). 
PKC mediates PMN activation and endothelial cell response during I/R injury
(Laudanna et al. 1998; Rahman et al. 2000; Dang et al. 2001; Young et al. 2001; Young
et al. 2005). In both cell types, PKC is a key enzyme in the signal transduction cascade
leading to the generation of SO release. PKC is a family of serine/threonine kinases with
isoforms that are classified into three different subfamilies based on their structure and 
regulation (Budhiraja et al. 2008). The classical PKC isoforms alpha, beta I, beta II, and 
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gamma are Ca
2+ 
dependent and activated by diacylglycerol (DAG). The novel PKC 
isoforms include delta, epsilon, eta and theta, which can be activated by DAG however 
2+ 2+
they are Ca independent. Finally, the atypical isoforms iota/lambda and zeta are Ca
and DAG independent, but can be activated by insulin and phosphatidylinositol 4,5­
bisphosphate (Ptdins(3,4,5)P2) (Dang et al. 2001; Young et al. 2005; Budhiraja et al. 
2008).
In both vascular endothelial cells and leukocytes, PKC isoforms reside in the
cytoplasm in an inactive form. Inflammatory cytokines such as TNF-alpha and IL-8
stimulate chemotatic G-protein coupled receptors, which in turn activates phospholipase
C (PLC) and phosphatidylinositol-3-kinase (PI3-kinase).  Next, second messengers such 
as Ca
2+
, DAG and Ptdins(3,4,5)P2 are generated which in turn activates PKC (Figure 3).
Additionally, PKC in neutrophils can also be activated by chemoattractants and C5a of 
the complement pathway (Young et al. 2005).
Once activated, PKC undergoes a conformational change which allows it to bind 
to a receptor for activated C-kinase (RACK) (Palaniyandi et al. 2009). RACKs are
membrane bound homologues of the beta unit of G-proteins. They stabilize activated 
PKC and facilitate its transport to the cell membrane where it can interact with its 
substrates, such as NADPH oxidase and eNOS (Park, Wu et al. 2004).  For example, 
while anchored to RACK, the activated PKC isoenzymes phosphorylate cytosolic factor 
p47 phox which increases NADPH oxidase activity (Peterman et al. 2004).  On the other
hand, PKC can regulate eNOS activity. Upon activation, PKC has the ability to 
phosphorylate eNOS and subsequently inhibit its activity which causes a reduction of
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endothelium-derived NO (Hirata et al. 1995). A schematic representation of PKC 
activation in the leukocyte and endothelium is presented in figure 3.
Figure 3. Schematic representation of PKC activation and interaction with its 
substrates in the leukocyte and endothelium. (Adapted from Young, Balin et al. 
2005)
Gö 6983, a bisindolylmaleimide analog, is a potent, fast acting inhibitor of some
classical (alpha, beta, gamma), novel (delta), and atypical (zeta) PKC isoforms. Gö 6983 
has a molecular weight of 442.5 and is a crystalline powder that is soluble in 
dimethylsulfoxide but can be diluted in aqueous solutions (Gschwendt M 1996). The
bisindolylmaleimides are synthetic analogs of the natural fungal metabolite staurosporine
but are  more selective for PKC within a wider concentration range (Jirousek et al. 1996).  
Bisindolylmaleimide I (i.e., Gö 6850) was the prototype compound that was developed in 
this group and has an opened central aromatic ring in contrast to staurosporine (Toullec D 
1991). Gö 6983 differs from Gö 6850 solely in a methoxy group substitution that allows 
this compound to inhibit the PKC zeta isoform in contrast to the other 
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bisindolymaleimides (Gschwendt M 1996). Gö 6983 acts at the ATP binding site which 
is highly conserved across PKC isoforms except for the zeta isoform (Hug et al. 1993).  
However, the methoxy group on Gö 6983 enables this compound to inhibit the zeta 
isoform within the low nanomolar range. 
Selective PKC Beta II inhibitor has a molecular weight of 1300 (N-Myr-
SLNPEWNET) (Genemed Synthesis, Inc., San Antonio, TX) and is myristoylated (fatty
acid moiety) to allow for rapid cell permeability (within 10 sec.)(Omiyi et al. 2005). This 
peptide inhibitor competitively inhibits the PKC Beta II isoform from binding to its 
RACK, thereby inhibiting PKC Beta II from being translocated to the cell membrane and 
interacting with its cellular substrates (i.e., p47 phox of NADPH oxidase and eNOS) 
(Korchak et al. 2001) Figure 4. 
Figure 4.  (a) A schematic depiction of a physiological response resulting from the
association of active PKC Beta II with its RACK and the phosphorylation of a 
phox
nearby protein substrate (e.g. p47 ). (b) PKC Beta II inhibition attenuates PKC 
Beta II translocation and function.  (PS, phosphatidylserine; DG, diacylglycerol; 
Ca, calcium). Adapted from (Csukai et al. 1999)
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Previous in vitro, ex vivo and in vivo work shows that compounds that decrease
oxidative stress by decreasing SO release restore post reperfused organ function (Young
et al. 2005). Inhibiting PKC activation causes an increase in eNOS activity and inhibits 
NADPH oxidase assembly. Studies performed with a broad spectrum PKC inhibitor (i.e.,
Gö 6983) and a selective PKC Beta II inhibitor have shown an increase in NO release in 
rat aortic segments in vitro and decreased leukocyte SO release in vitro as well as 
decreased leukocyte-endothelial interactions in vivo (Young, Balin et al. 2005(Chen et al. 
2010). Moreover, selective PKC Beta II inhibition attenuated extracorporeal shock wave
lithotripsy- induced oxidative stress increase in H2O2 release from renal veins in vivo
(Chen et al. 2010).  Substances that increase NO and decrease SO may attenuate 
reperfusion injury; therefore we would like to test compounds that regulate these
biomolecules in the femoral I/R model. The broad spectrum PKC inhibitor Gö 6983 and 
the selective PKC Beta II inhibitor have been previously shown in vitro to exert 
cardioprotective effects in rat cardiac ischemia/reperfusion (I/R) injury through 
attenuation of SO production in PMNs and vascular endothelium via NADPH oxidase
(Peterman et al. 2004; Omiyi et al. 2005). Moreover, previous studies have shown that a 
reduction in H2O2 release in the femoral I/R with selective PKC epsilon inhibitor
correlated with improved post reperfused cardiac function (Teng et al. 2008). 
We hypothesize that the femoral I/R vein will show an increase in H2O2 release
compared to their sham femoral vein. Whereas, a decrease in NO release is expected in 
the femoral I/R vein compared to the sham vein. This study shows the role of broad 
spectrum PKC inhibition by Gö 6983 or selective PKC Beta II inhibition in regards to 
their effects on NO and H2O2 release from femoral I/R and sham veins. If inhibition takes 
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place, then PKC will not be able to translocate to the cell membrane to activate NADPH 
oxidase leading to an overall decrease in H2O2 release during reperfusion in femoral I/R
veins compared to non-drug treated controls. Moreover, the broad spectrum PKC 
inhibitor or selective PKC Beta II inhibitor is predicted to increase NO release compared 
to non-drug controls.  
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Methods
Femoral I/R Preparation in Rat
The Institutional Animal Care and Use Committee (IACUC) of the Philadelphia 
College of Osteopathic Medicine approved all animal protocols in this study. Male
Sprague Dawley rats (275-325 grams, Ace Animals, Boyertown, PA) were anaesthetized 
with an induction dose of 60 mg/kg of sodium pentobarbital, intraperitoneally (i.p.). 
Sodium heparin (1.0 ml; 1,000 U, i.p.) was administered in conjunction with 
pentobarbital to prevent a coagulation reaction and subsequently allow the insertion of a
venous catheter and free radical sensors. Maintenance anesthesia (28 mg/kg, i.p.) was 
used if necessary.  
Recently, a novel technique was developed in order to measure H2O2 and NO
release from femoral veins in rats. H2O2 and NO sensors were calibrated with known 
H2O2/NO concentration standard solutions before every experiment. The anesthetized rat 
was placed in a supine position and the skin of the lower limbs was removed in order to 
isolate the femoral artery and vein on both sides. A suture was positioned under both 
femoral artery and vein to assist in placement of the ischemic clamp on one side. A 24 
gauge angio-catheter was cut to a length of approximately 5- 10 mm and then inserted 
into each femoral vein allowing for a microsensor (100 m, from World Precision 
Instruments, (WPI , Sarasota, FL)) to be inserted through the catheter into each vein. 
Once placed, the sensor was placed on a stack of 2”x2” 12-ply cotton gauze; this helped
to maintain the proper orientation in the catheterized vessel throughout the experiment
(Figure 5). The microsensors (either H2O2 or NO) were connected to a free radical gas 
analyzer (Apollo 4000 WPI), which allowed for real time measurements of NO or H2O2 
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release by an electrode picoamp (pA) response. The free radical of interest diffuses 
through a selective membrane covering into the sensor and is oxidized at the working
electrode, resulting in an electrical (oxidation/reduction) signal whose amplitude is 
proportional to the free radical concentration in the sample.  Each type of sensor has a 
selective poise voltage that is important for obtaining reliable data.  A high performance
Faraday shield incorporated in the sensor minimizes environmental noise (Zhang et al. 
2008).
Figure 5. Experimental setup of I/R in femoral limbs. 
Through a calibration curve, derived from known concentrations of H2O2 or NO, 
the pA response is converted to a molar concentration (discussed later). One limb was 
subjected to I/R by clamping the femoral artery and vein for 20 min. The clamp was then 
removed to induce reperfusion for 45 min. The other femoral artery/vein did not receive 
ischemia and served as a sham control. The femoral I/R time course is consistent with the 
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time periods set up for the myocardial I/R injury heart model to correlate a biochemical 
mechanism responsible for the improved post-reperfusion cardiac function (Young, Balin 
et al. 2005). 
The data were collected every 5 min throughout the experiment. Initially, baseline
recordings were made for the first 15 min (once the microsensors were placed in the
lumen of the vein and leveled out) from both femoral veins. During ischemia, we usually
observed a significant drop in NO/H2O2 traces in I/R limb compared to sham limb due to 
the blockade of femoral vein blood flow. At the onset of reperfusion, the drug diluted 
with saline (0.5ml with 0.5ml saline flush) or saline alone (1.0ml control group) was 
injected by a butterfly needle (25 gauge) through the tail vein of the rat. The H2O2 or NO
release recorded during 0-5 min of reperfusion is expressed as peak response.
Calibration Curve: From pA to Molar Concentration
Due to the microsensors sensitivity, they needed to be calibrated prior to each 
experiment.  H2O2 microsensors were calibrated by soaking the microsensor reference
part in 10 mL of phosphate buffered saline (PBS 0.01 M) until a stable trace was 
recorded on the monitor.  Next, a 1.0 mM H2O2 solution was prepared with deionized 
water.  A concentration response curve was generated by placing 0 nM- 2 M of the
H2O2 solution in the PBS solution. The calibration curve for H2O2 was linear over a
concentration range of 250-2000 nM and had a sensitivity of approximately 2.5 pA/nM. 
NO microsensors were calibrated by soaking them in a 10 mL solution of copper
sulfate (0.1 M) until a stable trace was recorded on the monitor. A solution containing 
deionized water, ethylene diamine tetra-acetic acid (EDTA), and S-nitroso-N-acetyl-l,l­
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penicillamine (SNAP), an NO donor was prepared. When exposed to Cu
2+ 
ion, SNAP
quantitatively decomposes to NO and a disulfide product:
In theory, the concentration of NO generated should be equal to the final 
concentration of SNAP in the copper sulfate solution.  In practice, some NO is 
immediately oxidized to nitrite and not detected by the sensor.  Furthermore, SNAP
decomposition does not go to completion even in the presence of a catalyst (Chen et al. 
2010).  Consequently, the detected NO is about 60% of the SNAP concentration.  The
calibration curve for NO is generally linear over a concentration range of 10 to 200 nM 
SNAP, and the sensitivity should be about 10 pA/nM.  
For both H2O2 and NO sensors, the response from their corresponding solutions 
produced a stepwise, dose-response curve. This enabled a calibration curve to be 
constructed; using the slope of this curve, the computer generated pA response to either 
H2O2 or NO was converted to a molar concentration. For H2O2, a M range was used, 
while NO was converted into a nM concentration because of the smaller trace amounts of 
the molecule in blood vessels. Figure 6 represents a sample calibration curve for H2O2. 
The relative change of H2O2 or NO current was calculated by subtracting the last 
baseline value. Then the relative current change was converted into H2O2 or NO 
concentration based on the calibration curve. For evaluating the drug‟s effects, the
different H2O2 or NO levels were calculated by using the free radical levels in I/R limb 
minus sham limb.
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y = 0.9293x - 26.892 
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Figure 6. Sample Calibration Curve for H2O2.
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Control/Drug treated groups
Group 1- H2O2 Control (n=7) One limb was subjected to I/R while the other 
limb was a sham (no I/R). Saline (0.9%, 1.0 mL) is injected through the tail vein at the
onset of reperfusion. This group serves as a control to reflect the relative change of H2O2 
levels between I/R and sham limbs under I/R conditions. 
NO Control (n=6) This group followed the same protocol as the H2O2 control but used
an NO electrode.
Group 2- H2O2 release with administration of Gö 6983 (n=7) At the onset of 
reperfusion, Gö 6983 was administered through the tail vein (7.4 g/kg), dissolved with 
0.5 mL of saline followed by a flush of 0.5 mL of 0.9% saline. This converts to 
approximately 200 nM of Gö 6983 in blood. This group aims to evaluate the effect of Gö 
6083 on H2O2 levels under I/R conditions.
NO release with administration of Gö 6983 (n=7) This group followed the same
protocol as the H2O2 with Gö 6983 but used a NO electrode.
Group 3- H2O2 release with administration of PKC β II inhibitor (n=7) At the 
onset of reperfusion, PKC β II inhibitor was administered through the tail vein (0.55 
mg/kg), dissolved in 0.5 mL of saline (0.9%) followed by a flush of 0.5 mL of 0.9%
saline. This converts to approximately 10 M of PKC β II inhibitor in blood. This group 
aims to evaluate the effect of PKC β II inhibitor on H2O2 levels under I/R conditions.
NO release with administration of PKC β II inhibitor (n=6) This group followed the 
same protocol as the H2O2 with PKC β II inhibitor but used a NO electrode.
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Statistical Analysis
All data in the text and figures were presented as means ± SEM. The relative
differences in H2O2 or NO levels from femoral I/R and sham veins within the saline
injected (non-drug) control groups was compared to drug treated groups by analysis of 
variance (ANOVA) using post hoc analysis with the Fisher PLSD test. This will be
known as the "between groups" comparison. Differences in H2O2 or NO release between 
femoral I/R and sham veins was analyzed by a student's t-test, this will be known as the 
"within groups" comparison. Probability values of <0.05 are considered to be statistically
significant.
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Results
Figure 7 shows a real time measurement of H2O2 in a sham femoral vein and an
I/R femoral vein from the same animal at the onset of reperfusion analyzed by Apollo
4000 free radical analyzer. Upon reperfusion (i.e., when the clamp is released from the
femoral artery and vein) an increase in the computer generated pA response was observed
in the I/R limb, however the sham limb remained relatively stable.
Figure 7. H2O2 release from femoral veins: The onset of reperfusion
All graphs in this section and throughout the thesis were measured as relative
changes. A relative change graph arbitrarily sets the final baseline at the y-intercept from 
the calibration curve for NO or H2O2 sensor. When treatment decreased or increased
H2O2/NO release, it was represented as a change from initial baseline to a negative or 
positive number on the graph. 
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H2O2 Release
Figure 8 shows H2O2 release in a saline control group, which is a “within group”
experiment. The I/R femoral vein showed a significant (p< 0.05) increase in H2O2 release
from the peak H2O2 response (i.e., between 0-5 min) to 45 min post- reperfusion
compared to the sham femoral vein. Thus, H2O2 was approximately ~2-3 M higher in 
the I/R femoral vein than in the sham throughout reperfusion. 
Figure 8.  The time course of change in H2O2 ( M) release from rat femoral veins 
during reperfusion in the control group.  Anesthetized rats were given a saline I.V. 
at the beginning of reperfusion (n=7).  There was a significant increase in H2O2 
release from I/R veins compared to sham veins during reperfusion (**p<0.01 from
sham, * p<0.05 from sham).
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In figure 9 the difference between the I/R limb and the sham limb is compared. 
There was a significant (p< 0.01) increase in H2O2 release throughout reperfusion
compared to the initial baseline H2O2 levels, that ranged from 2 to 2.8 M. 
Figure 9.  The relative difference in H2O2 release between I/R and sham femoral 
veins during reperfusion in the control group.  Anesthetized rats were given a saline
I.V. at the beginning of reperfusion (n=7).  There was a significant increase in H2O2 
throughout reperfusion compared to initial baseline H2O2 levels (**p<0.01 from
baseline, * p<0.05 from baseline).
Figure 10 represents a between groups graph illustrating the effects of broad 
spectrum PKC inhibitor Gö 6983 (7.4 g/kg) or selective PKC β II inhibitor (0.55 mg/kg)
on H2O2 release compared to saline control. The difference between I/R and sham 
femoral veins were plotted and compared to Gö 6983 and PKC β II inhibitor. Both drugs 
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used proved effective in attenuating the increase in H2O2 caused by I/R injury. Gö 6983 
and PKC β II inhibitor significantly (p< 0.01) decreased between 1.5- 2.5 M H2O2 
released from 20 min and 15 min post reperfusion respectfully on through to the end of
the 45 min experimental timeline.  
Figure 10.  The relative difference in H2O2 release between I/R and sham femoral 
veins during reperfusion. Anesthetized rats were given a saline control (n=7) or Gö 
6983 (n=7) or PKC β II inhibitor (n=7) I.V. at the beginning of reperfusion.  There
was a significant decrease in H2O2 release in drug treated groups compared to saline
control. (**p<0.01 from saline for Gö 6983, * p<0.05 from saline for Gö 6983, ##
p<0.01 from saline for PKC β II inhibitor, # p<0.05 from saline for PKC β II 
inhibitor).
NO Release
Figure 11 shows the NO release in the saline control group. The I/R femoral vein
showed a trend to decrease more than the sham vein over the 45 min reperfusion period. 
The slope of the I/R vein was -11 whereas the slope of the sham vein was -4. 
Nonetheless, there was not a significant change between each vein for NO release. The
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I/R vein showed a transient increase in NO release during the first 5 min post reperfusion, 
but continued to decrease throughout reperfusion dropping to -25 below baseline at the
end of reperfusion (45 min). 
Figure 11. The change in NO (nM) release from rat femoral veins during 
reperfusion in the control group.  Anesthetized rats were given saline I.V. at the
beginning of reperfusion (n=6).  There was no significant difference in NO release
from I/R veins compared to sham during reperfusion.
In figure 12 the difference between the I/R limb and the sham limb were
compared. There was a significant increase in NO release of 70 nM during the initial 
peak NO response (i.e., 0-5 min) compared to the initial baseline NO levels (p< 0.01). 
However, throughout the remaining 45 min of reperfusion there was no significant 
difference between the post-reperfusion NO levels compared to the baseline NO levels. 
This comparison will be applied to the drug treated groups as well. 
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Figure 12. The relative difference in NO release between I/R and sham femoral 
veins during reperfusion in the control group.  Anesthetized rats were given a saline
I.V. at the beginning of reperfusion (n=6).  There was a significant increase in NO
during the NO peak response after onset of reperfusion compared to initial baseline
NO levels (**p<0.01 from baseline).
Figure 13 represents a between groups graph illustrating the effects of broad 
spectrum PKC inhibitor Gö 6983 (7.4 g/kg) or selective PKC β II inhibitor (0.55 mg/kg)
on NO release compared to saline control. The difference between I/R and sham femoral 
veins were plotted and compared to Gö 6983 and PKC β II inhibitor. Both drugs 
increased the blood NO levels after reperfusion. Gö 6983 significantly increased NO 
levels between 100-150 nM for the entire 45 min reperfusion period compared to saline
control (p< 0.01). However, PKC β II inhibitor showed an increase in NO levels between 
50-75 nM compared to saline control (p< 0.05) but was only significant at 40 and 45 min 
post-reperfusion. 
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Figure 13. The relative difference in NO release between I/R and sham femoral 
veins during reperfusion. Anesthetized rats were given a saline control (n=6) or Gö 
6983 (n=7) or PKC β II inhibitor (n=6) I.V. at the beginning of reperfusion.  There
was a significant increase in NO release in drug treated groups compared to saline
control. (**p<0.01 from saline for Gö 6983, * p<0.05 from saline for Gö 6983, # 
p<0.05 from saline for PKC β II inhibitor).
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Discussion
Summary of Findings
The major findings of this study were as follows: 1) H2O2 release was
significantly higher throughout the 45 min reperfusion period in the I/R femoral vein 
compared to a sham femoral vein in the saline control group. There was no significant 
difference in the NO release between the I/R and sham femoral veins in the saline control 
group. 2) The addition of Gö 6983 (7.4 g/kg) showed a significant decrease in H2O2 
release from 20-45min post-reperfusion and a significant increase in NO release
throughout the entire 45 min of reperfusion compared to saline control when given I.V. at 
the beginning of reperfusion. 3) PKC β II inhibitor (0.55 mg/kg) given at the start of 
reperfusion significantly decreased H2O2 release from 15- 45 min post-reperfusion
compared to saline control. PKC β II inhibitor (0.55 mg/kg) also significantly increased
NO release compared to saline control at 40 and 45 min post-reperfusion. 
Measuring H2O2 release versus NO release in Femoral I/R: Non Drug Control 
Groups
The saline control group showed a significant increase in H2O2 release in I/R
femoral veins during reperfusion compared to sham femoral veins. The sham vein 
continued to drop throughout the time course of the experiment due to the decreased body
temperature and the effects of the anesthesia. The increase in H2O2 in the I/R femoral 
vein can be attributed to multiple sources of SO during reperfusion. In the setting of I/R, 
NADPH oxidase from endothelial cells/leukocytes, uncoupled eNOS, and incomplete 
ATP synthesis in mitochondria are sources of SO. The SO release from mitochondria can 
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oxidize BH4 to BH2, causing an increase in the BH2/BH4 ratio. Under these conditions, 
eNOS becomes uncoupled and principally produces SO instead of NO. Therefore, 
uncoupled eNOS can also be a significant source of oxidative stress during reperfusion. 
Previous work showed that inhibiting eNOS activity during reperfusion attenuated H2O2 
release in blood (Teng et al. 2008). Recalling that SOD converts SO to H2O2, during
these real time results, H2O2 served as an indirect measure for SO.
Figure 11 shows that at the onset of reperfusion, NO showed a trend to increase in 
the I/R femoral vein compared to a sham femoral vein although not significant. However, 
Figure 12 shows that the peak NO response significantly increased compared to the initial 
baseline. This may be due to factors such as shear wall stress and an initial surge in blood 
supply to femoral circulation once the clamp was removed from the artery and vein. 
However at 25 min post-reperfusion, the I/R vein showed a trend to decrease NO release
when compared to the sham vein although not significant (Figure 11). This finding is not 
consistent with our hypothesis in that we expected to have a significant decrease in the
I/R compared to sham vein. This may be due to more coupled eNOS under these I/R
conditions suggesting that NADPH oxidase may be the principal source of the SO 
release. These findings are consistent with the notion that the increased H2O2 release in 
the femoral I/R vein is primarily attributable to NADPH oxidase activation more, than to 
eNOS uncoupling. However, it should be emphasized that eNOS uncoupling can still be a
source of oxidative stress in this model since a previous study showed that principally
inhibiting eNOS activity during reperfusion resulted in reduced H2O2 release (Teng et al. 
2008). In support of this concept, administration of BH4 and/or inhibition of NADPH 
oxidase has been shown to improve post-reperfusion cardiac function and reduce H2O2 
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release in femoral I/R (e.g., BH4) (Ikeda et al. 2001; Chen et al. 2010).
Mechanisms Responsible for Changes in Femoral Vein H2O2 and NO Release
Reperfusion injury is characterized by endothelial dysfunction that occurs within 
the first 5 min of reperfusion. Endothelial dysfunction is characterized by increased 
oxidative stress (i.e., SO/H2O2 release) combined with attenuated NO bioavailability. SO 
attenuates the bioavailability of NO through the formation of peroxynitrite anion 
(Vasquez-Vivar et al., 2002). Endothelial dysfunction promotes an inflammatory reaction 
characterized by increased leukocyte-endothelial interactions. The time course for
significant leukocyte tissue infiltration in vivo is 3-4 hrs post-reperfusion after acute 
prolonged ischemia (Tsao et al. 1990). However, since the time course of reperfusion in 
this model is 45 min, PMNs are most likely not contributing to the significant increases in 
H2O2 release in I/R injury. 
Therefore, we attribute the increase in H2O2 release primarily to the production 
of SO by endothelial cells.  During the early reperfusion period (5 min), PKC activation 
and cell membrane expression are enhanced (Strasser et al. 1992).  PKC isozymes 
translocate on activation from one cellular compartment to another.  RACKs are the 
receptor proteins responsible for translocation from the cytosol to the cell membrane and 
subsequent function of PKC isoforms (Ron et al. 1995).  Activated PKC isoforms bind to 
their specific RACK-1 binding site, which increases the PKC isoform phosphorylation of 
substrates (i.e., NADPH oxidase, eNOS) by stabilizing the active PKC and translocating
it to the cell membrane (Ron et al. 1995).  The results of the present study suggest that 
PKC phosphorylates the cytosolic factor, p47phox, which then activates NADPH oxidase
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in endothelial cells and PMNs.  NADPH oxidase then converts oxygen to SO (Lefer et al. 
1996; Vasquez-Vivar et al. 2002; Chen et al. 2010). 
Effects of Gö 6983 on H2O2 / NO release
PKC is known to interact with other substrates such as myocardial contractile 
proteins and mitochondrial potassium ATP channels. However, these substrates are
probably not involved since the concentration of Gö 6983 used in this model did not elicit 
cardiotonic or cardio-depressant effects in sham hearts (Peterman et al. 2004). Moreover, 
mitochondrial ATP channels are important in inducing myocardial preconditioning which 
is an adaptive response to protect organ function from prolonged ischemia. 
Preconditioning was not induced in this model and therefore would not influence H2O2 or
NO levels in our femoral I/R model. Additionally, Gö 6983 has been shown to reduce L­
NAME induced leukocyte-endothelial interactions in the rat mesenteric circulation in real 
time (Chen et al. 2010). Therefore, we believe that the principal target for the antioxidant 
action was endothelial cells.
As previously mentioned, Gö 6983 significantly decreased H2O2 release (Figure
10) and increased NO (Figure 13) bioavailability when given at the beginning of 
reperfusion in the femoral I/R injury model. These effects of Gö 6983 are most likely due
to the inhibition of NADPH oxidase in vascular tissue (i.e., eNOS endothelial cells, 
nNOS vascular smooth muscle cells) (Young et al. 2005). This effect may be mediated by
inhibiting PKC activation  therefore, suppressing SO release from vascular tissue via
NADPH oxidase inhibition, and the increasing NO release from endothelial cells through 
activation of coupled eNOS (Lefer et al. 1996; Zhang J 1999).  
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During I/R injury, NADPH oxidase activity from both PMNs and vascular tissue 
generates the reactive oxygen species that account for oxidative damage and ensuing
endothelial dysfunction (Hansen, 1995; Ma et al., 1991). Increasing NO release from the 
endothelium, can quench excess SO, therefore, effectively attenuating oxidative stress 
during reperfusion (Buerke et al. 1994).
In this study, the significant increase in vascular NO release can possibly be
attributed to inhibition of PKC by Gö 6983.  Previous studies indicate that activating
PKC with PMA, a broad spectrum PKC agonist, inhibits NO release due to inhibition of
eNOS (Rubanyi et al. 1986), whereas inhibiting PKC with a broad spectrum PKC 
inhibitor (i.e., Gö 6983) allows for an increase in NO production from coupled eNOS
(Young et al. 2005). Moreover, selective inhibition of PKC beta II, delta, and zeta 
isoforms increased vascular NO release in vitro (Young et al. 2006). It would be expected 
that Gö 6983 would exert greater NO release than PKC beta II inhibitor in vivo. 
Collectively, I/R injury is associated with activated PKC that in turn would exacerbate 
tissue injury (i.e., oxidative stress) during reperfusion and these effects could be 
countered by Gö 6983. Therefore, inhibiting oxidative stress via NADPH oxidase and 
enhancing eNOS activity with Gö 6983 provides a rationale to account for the
decreased/increased H2O2 and NO release respectively in femoral I/R.
Previous studies demonstrated that Gö 6983 inhibits the SO release from PMNs
and augments NO release from vascular tissue (i.e., rat aortic segments) (Young et al. 
2005). Gö 6983 is a bisindolymaleimide that is structurally similar to the potent PKC 
inhibitor staurosporine (Gschwendt M 1996).  As previously shown with staurosporine, 
Gö 6983 inhibits the respiratory burst generated by activated PMNs and restores post­
                                                                              
                                                                          
 
 
  
  
 
 
  
     
 
        
  
  
  
   
  
  
     
  
  
   
 
  
 
33
reperfusion cardiac function (Young et al. 2001). Also similar to staurosporine, Gö 6983 
enters the cell via simple diffusion and inhibits PKC by binding to its ATP binding site
(Toullec D 1991; Numaguchi et al. 1996). However, in contrast to staurosporine, Gö 
6983 inhibits the PKC zeta isoform and this effect is correlated with better post­
reperfused cardiac function and greater attenuation of SO release by PMNs compared to 
staurosporine (Young et al. 2005). The findings in this study support the conclusions of
Gschwendt et al. (1996) in that Gö 6983 provides better attenuation of oxidative stress 
compared to selective PKC inhibitors.
Recent studies have shown that PKC zeta and beta II are principally responsible
for activating SO release through NADPH oxidase (Laudanna et al. 1998; Kilpatrick et 
al. 2000; Rahman et al. 2000; Dang et al. 2001). Therefore, inhibiting both of these
isoforms with Gö 6983 provides a rationale for a greater effect on increasing NO
bioavailability through these mechanisms.
Effects of PKC β II inhibitor on H2O2/NO release
This study also showed that PKC β II peptide inhibition results in attenuation of
endothelial dysfunction by decreasing SO/H2O2 release through NADPH oxidase and 
increasing NO release from coupled eNOS, which leads to an increase in the
bioavailability of NO. As previously mentioned, oxygen-derived free radicals such as SO 
quench endogenous NO to form peroxynitrite anion (Patel KD 1991; Davenpeck KL
1994). NO inhibits leukocyte-endothelial cell interactions, thereby attenuating later 
inflammation mediated tissue injury (Davenpeck KL 1994; Gauthier et al. 1994; Lefer et 
al. 1996).
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PKC β II translocates from cytosol to cell membrane after activation by second 
messengers (i.e. DAG). RACKs are the receptor proteins responsible for translocation 
and subsequent function of a PKC enzyme (Ron et al. 1995). Activated PKC β II binds to
its specific RACK-1 binding site, which increases the phosphorylation of substrates (e.g. 
NADPH oxidase, eNOS), by stabilizing the binding of the active form of PKC β II  to the
cell membrane (Ron et al. 1995). NADPH oxidase activation in both PMNs and vascular 
tissue generates reactive oxygen species (e.g. SO), which cause oxidative damage and 
perpetuates cardiac contractile dysfunction (Ma et al. 1991; Hansen 1995). The PKC β II
peptide inhibitor occupies the RACK-1 binding site preventing the binding of PKC β II. 
Therefore inhibiting the translocation of the activated PKC β II isoform and its function 
of activating NADPH oxidase in vascular tissue/PMNs and inhibiting coupled eNOS
decreases oxidative stress in reperfusion injury (Hirata et al. 1995; Korchak et al. 2001).
Moreover, PKC β II inhibition would increase eNOS activity leading to enhanced 
NO release in blood (Omiyi et al. 2005; Young et al. 2005). Collectively, the effects of 
PKC β II inhibitor on NADPH oxidase and eNOS provides a rationale to account for the
significant decrease/increase in H2O2 and NO release respectively during reperfusion
compared to saline control. However, these effects were less than those seen with Gö 
6983 regarding NO but similar regarding H2O2. This may be due to Gö 6983 inhibiting
both beta and zeta for optimal inhibition of NADPH oxidase and activation of coupled 
eNOS(i.e., beta, zeta, delta).  Regarding NO, Gö 6983 via inhibition of beta, zeta, and 
delta isoforms may optimally enhance activation of coupled eNOS to produce more NO 
release compared to selective inhibition with PKC β II. Regarding H2O2, both Gö 6983 
and PKC β II inhibitor attenuated H2O2 release to near initial baseline levels, this 
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suggests that additional isoform inhibition with Gö 6983 would not produce a greater
effect compared to PKC β II inhibitor. Collectively, these results suggest that the PKC β 
II isoform exerts a significant effect on NADPH oxidase activity (Kilpatrick et al. 2000).
Physiological Significance
Previous work has shown that reducing H2O2 release and subsequently increasing
the bioavailability of NO in femoral I/R correlates with improved post-reperfused cardiac
function as well as attenuation of leukocyte-endothelial interactions in the mesenteric 
circulation (Young, Balin et al. 2005). Clinically, these tools (i.e., Gö 6983 or selective
PKC β II inhibitor) can be used as effective pharmacological aids in reducing oxidative 
stress associated with clinical organ transplantation or lower limb trauma as demonstrated 
in this study. These tools can also be used clinically in decreasing the oxidative stress 
associated with reperfusion injury in ischemic events such as MI and stroke and coronary
angioplasty.
Future Studies
To further elucidate the role of eNOS uncoupling during reperfusion, other
regulators of eNOS activity could be used in conjunction with BH4 or BH2 in myocardial 
and femoral I/R studies. For example, arachidonic acid is known to inhibit the association 
of eNOS with L-arginine and therefore may possibly promote eNOS uncoupling. 
Inhibiting the mobilization of arachidonic acid may attenuate the potential uncoupling
effect of fatty acids on eNOS activity and potentially identify another pharmacological 
tool that may be useful at attenuating reperfusion injury (Weis et al. 2004). Also High 
Performance Liquid Chromatography (HPLC) will be performed on the blood and tissue 
samples taken from the femoral I/R animals. This will provide an understanding of the
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BH4 and BH2 content. Determining the ratio of BH2/BH4 after reperfusion will provide an 
estimate of the level of eNOS uncoupling due to oxidative stress.
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